Tiger Balm External Analgesic Firm Scratched Again On US GMP Violations
Inspection in February and March found GMP violations including failing to thoroughly investigate unexplained batch discrepancies or failures, regardless of whether it already is distributed, are repeats from 2010 problems FDA found at Haw Par Healthcare.
You may also be interested in...
House subcommittee approves DXM Abuse bill; UK ire for US firm’s patch claims; Innophos VP hire; and more news in brief.
A number of recent FDA warning letters focused on GMP issues with aseptic processing, signaling the agency’s continuing concern about contamination prevention.
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.